Paediatric BMTPaediatric CAR-TPrivate · Tertiary (Grade 3)Changping, BeijingLeading Paediatric BMT Center
Jingdu Children's Hospital A Leading Center for Paediatric Blood Cancers & BMT
The national reference center for paediatric haematological malignancies and bone marrow transplantation in China. For a child with leukaemia, lymphoma, or another blood cancer requiring bone marrow transplantation or CAR-T cell therapy, Jingdu may be a suitable option — its paediatric haematology team is among the most experienced in the country, with parent accommodation throughout every admission. China Care helps you work out whether it's the right fit for your child's case.
Changping District, Beijing — ~45–60 min from Beijing Capital Airport
Quick Facts
Payment
Paid directly to hospital — international bank transfer; hospital confirms payment method before admission
Consultation
Remote case review by paediatric haematology team within 3–5 days; video consultation before travel
Advance Booking
1–2 weeks minimum after remote review
Language
Bilingual coordination provided by China Care throughout; Chinese-speaking ward staff
Type
Private tertiary (Grade 3) children's hospital · Major paediatric BMT center · Changping, Beijing
BMT Leader
One of China's largest paediatric transplant programmes
CAR-T
Paediatric cell therapy programme
Private Tertiary
Highest private hospital grade
Family Rooms
Parent accommodation throughout admission
About the Hospital
Where Paediatric Haematologists Send Their Hardest Cases
Jingdu Children's Hospital (北京京都儿童医院), established in 2015 and JCI-accredited since 2020, is a private tertiary (Grade 3) children's specialist hospital in Changping District, Beijing. Despite its private status, it is one of China's largest private centers for paediatric bone marrow transplantation and haematological malignancies — a national-calibre programme more often associated with large public children's hospitals. The haematology department has one of the highest paediatric BMT volumes among private hospitals in China.
The hospital has progressively expanded into CAR-T cell therapy for paediatric patients with relapsed or refractory acute lymphoblastic leukaemia (ALL) and other blood cancers. For families researching CAR-T cell therapy in China, Jingdu offers one of the few programmes specifically designed and staffed for paediatric cases. Paediatric CAR-T protocols differ meaningfully from adult protocols in manufacturing specifications, dosing parameters, and toxicity management — particularly cytokine release syndrome (CRS) grading. Jingdu's team has direct experience navigating these paediatric-specific differences.
The private tertiary (Grade 3) designation means the hospital maintains public hospital-equivalent clinical standards while operating with private hospital-level accommodation. International parents are accommodated in the same room as their child throughout admission, including during bone marrow transplantation.
"For paediatric bone marrow transplantation in China, this is the hospital where other paediatric haematologists send their hardest cases."
Why Patients Choose Jingdu
Three Reasons International Families Choose Jingdu
National Authority for Paediatric BMT
Jingdu has performed more paediatric bone marrow transplants than any comparable hospital in China. The procedural depth — conditioning protocols, graft engineering, engraftment monitoring, GVHD management — is the product of sustained high-volume experience with the most complex paediatric cases in the country.
CAR-T Cell Therapy for Paediatric Blood Cancers
The paediatric CAR-T programme covers relapsed/refractory ALL, lymphoma, and selected AML cases in children. Paediatric CAR-T protocols differ from adult protocols in manufacturing specifications, dosing, and toxicity management. Jingdu's paediatric haematology team has direct expertise in these paediatric-specific differences.
Private Tertiary, Family-Centred Accommodation
Tertiary (Grade 3) accreditation means clinical standards equivalent to China's leading public children's hospitals. The private setting means parents stay in the room throughout admission — meals included for the accompanying parent. The ward environment is calm and child-appropriate rather than the crowded public paediatric wards typical elsewhere in China.
Beyond the Hospital
Why Families Work With China Care
Finding a hospital's name is easy. Knowing whether it's actually the right one for your child's case is much harder — that's where China Care helps.
Most international families researching Jingdu are unsure whether it's genuinely the right fit for their child's diagnosis, or whether another hospital might serve them better. China Care helps you answer questions like:
Is Jingdu suitable for my child's diagnosis?
Are there better hospitals for my child's condition?
Can my child's case be reviewed before we travel?
Is BMT, CAR-T, or another approach more appropriate?
Paediatric Haematology Services Available to International Patients
Jingdu's clinical depth is concentrated in paediatric haematological malignancies, bone marrow transplantation, and CAR-T therapy.
Primary Focus
Paediatric Haematology
Comprehensive haematological malignancy programme covering all childhood blood cancers. Acute lymphoblastic leukaemia (ALL) is the highest-volume diagnosis, but the team has deep experience with AML, lymphoma, and myelodysplastic syndrome (MDS). Molecular profiling guides risk stratification.
ALLLymphomaAMLMDS
Primary Focus
Bone Marrow Transplantation
One of China's largest paediatric BMT programmes. Allogeneic (matched sibling, matched unrelated, haploidentical parent-donor) and autologous transplantation. Cord blood transplantation available. Conditioning protocol selection, graft engineering, GVHD management all handled by the dedicated transplant team.
Paediatric CAR-T programme for relapsed or refractory ALL, lymphoma, and selected AML cases. CD19-targeted and CD22-targeted constructs for B-cell malignancies. Paediatric-specific dosing and toxicity management protocols for CRS and ICANS.
Paediatric CAR-TCD19CD22
Also Available
Supportive Care
Comprehensive supportive care throughout BMT and CAR-T treatment. Infection control in the post-transplant period. Nutritional support including total parenteral nutrition. Psychological support for children and families undergoing the transplant process.
GVHD ManagementInfection ControlNutritional Support
Also Available
Post-BMT Monitoring
Structured long-term follow-up for transplant survivors. Remote monitoring enabling families to return home while maintaining regular contact with the Jingdu transplant team via telemedicine. Immunological recovery, late-effects surveillance, and re-vaccination scheduling included.
Hospital Access reviews your child's haematology records, identifies whether BMT, CAR-T, or another approach is appropriate, and confirms whether Jingdu — or another hospital — is a suitable option, before you commit to travelling.
How China Care Helps You Reach Jingdu — If It's Right for Your Child
Finding a hospital is the easy part. Understanding whether it's the right one for your child's situation is harder — China Care guides you through that, from initial guidance through to on-the-ground support in Beijing.
Step 1 · Tell Us What You Need
Submit Your Child's Haematology Records to China Care
Send complete haematology records including bone marrow biopsy results, immunophenotyping, cytogenetics and molecular profiling (FISH, PCR, NGS where available), prior treatment history including drug names and response data, and current disease status. China Care prepares a bilingual case summary within 1–2 working days.
complete haematology records required
Step 2 · Hospital Access
China Care Registers Your Child's Case and Confirms Eligibility
Hospital Access submits your bilingual case summary to Jingdu's paediatric haematology team and confirms whether this hospital is genuinely a suitable option for your child's case, and your appointment details, before you commit to travelling. The lead haematologist reviews the case and determines whether BMT, CAR-T, or a combination approach is most appropriate. This remote eligibility assessment typically takes 3–5 days. No in-person proxy visit is required before travel.
This is a fixed-fee service, agreed with you upfront.
Hospital Access · fixed fee · remote review 3–5 days
Step 3 · In-Person Consultation
Travel to Beijing for Your In-Person Consultation
Travel to Beijing for your first in-person consultation. The paediatric haematology specialist reviews your child's case in person, confirms the treatment plan, and provides a formal cost estimate at this appointment. China Care coordinator accompanies you throughout. All ward staff communicate primarily in Mandarin — bilingual coordination by China Care is essential throughout the admission.
in-person consultation · treatment plan issued
Step 4 · Medical Journey
Admission & Treatment — Parent Accommodation Included
Admission, conditioning chemotherapy, transplant or CAR-T infusion, and early post-procedure monitoring all take place at Jingdu, with a parent in the room throughout. A dedicated parent bed is provided in each room; meals provided for the accompanying parent. Payment is made directly to the hospital via international bank transfer, as confirmed by the hospital's finance team before admission. China Care coordinator available throughout.
parent room throughout · payment direct to hospital
Step 5 · Medical Journey
Discharge & Remote Follow-Up
When your child is stable for discharge, a structured remote follow-up protocol allows the family to return home while maintaining regular contact with the Jingdu transplant team via telemedicine. Detailed English discharge documentation is provided for your child's home physician. China Care facilitates communication between the Jingdu team and your home physician throughout follow-up.
remote follow-up · bilingual discharge docs
Bilingual case preparationRemote eligibility reviewVideo consultation availableParent room throughout admissionEnglish discharge documentationRemote post-discharge follow-upChina Care coordination
Before You Travel
What international families need to know
Payment
Direct to hospital
International bank transfer. Hospital confirms payment schedule before admission. Deposit required at admission; balance settled before discharge.
Advance Booking
1–2 weeks minimum
Remote case review first (3–5 days), then travel confirmed once eligibility is assessed. No walk-in for international paediatric cases.
Consultation Type
In-person for treatment
Remote case review and video consultation possible, but final treatment plan and BMT/CAR-T are confirmed in person on arrival.
Language
Bilingual via China Care
Ward staff operate in Mandarin. China Care provides full bilingual coordination throughout admission. Essential for all paediatric haematology admissions.
From Airport
~45–60 min
From Beijing Capital International Airport (PEK) by taxi or private transfer. Changping District. China Care provides accommodation recommendations near the hospital.
Hospital Type
Private Tertiary (Grade 3)
A private tertiary (Grade 3) children's hospital. One of China's largest private paediatric BMT centers. Private setting with family accommodation throughout.
Your Next Step
How China Care Can Help
Whichever stage you're at, China Care's role is the same: help you make an informed decision, not just a booking.
How is Jingdu different from NCICH, and which should I choose?
NCICH is a general private children's hospital appropriate for most paediatric conditions — general paediatrics, surgery, ENT, oncology support, and NICU. Jingdu is a specialist center concentrated entirely on paediatric haematological malignancies, bone marrow transplantation, and CAR-T. If your child has leukaemia, lymphoma, or another blood cancer and needs BMT or CAR-T, Jingdu is generally the more suitable option — it has more paediatric transplant experience than any other hospital in China. For general paediatric care or supportive oncology without BMT/CAR-T, NCICH is more accessible. China Care can help confirm which is right for your child's specific case.
What are the eligibility criteria for paediatric CAR-T at Jingdu?
The primary indication is relapsed or refractory B-cell ALL that has not achieved remission with at least two prior lines of therapy, or that has relapsed after BMT. CD19 and CD22-targeted constructs are available for B-cell malignancies. Selected lymphoma and AML cases are reviewed individually. Eligibility requires adequate organ function, sufficient performance status, and absence of active uncontrolled infection. The Jingdu team assesses eligibility during case review and confirms at the video pre-consultation.
How does the bone marrow donor matching process work for international patients?
Jingdu performs matched sibling donor, matched unrelated donor, haploidentical parent-donor, and cord blood transplantation. For international patients, haploidentical parent-donor transplantation is often the most practical route as it requires only a parent as the donor — no international registry search needed. Where a sibling is available and HLA-typed, matched sibling transplantation remains the preferred option. The haematology team discusses donor options during case review and video consultation.
How long does a typical BMT admission last?
A paediatric allogeneic BMT typically requires approximately 6–8 weeks of inpatient admission covering conditioning chemotherapy, graft infusion, engraftment monitoring, and early post-transplant recovery. After discharge, an additional 4–8 weeks of outpatient monitoring in Beijing is usually required. Total time in Beijing for a straightforward BMT is typically 3–4 months. CAR-T admissions are shorter — typically 4–6 weeks for infusion and monitoring. China Care provides accommodation recommendations near the hospital.
What are the parent accommodation arrangements during BMT?
Parents stay in the room with their child throughout inpatient admission, including during BMT and CAR-T phases. A dedicated parent bed is provided in each room. Meals are provided for the accompanying parent. Access is controlled during the most critical sterile phases — one parent at a time — with flexibility during recovery. Jingdu's nursing staff involve parents actively in the care plan and communicate progress updates directly to families.
What happens after we return home — how is follow-up managed?
Jingdu operates a structured remote follow-up protocol for international transplant patients. After discharge, the family receives a detailed monitoring schedule specifying required blood tests, chimerism assessments, and clinical reviews. Results are shared digitally with the Jingdu transplant team who review them and communicate any concerns via telemedicine. China Care facilitates communication between the Jingdu team and your home physician throughout the follow-up period.
Still Deciding?
Not every hospital is the right fit for every child
We'll help you understand whether Jingdu Children's Hospital — or another hospital in China — may be a better option for your child's situation.
China Care coordinates your referral to Jingdu Children's Hospital's paediatric haematology team. Treatment costs are quoted directly by the hospital. We never add to, inflate, or mark up the hospital's quoted treatment cost.
Hospital profile note: This profile is general reference information. China Care does not endorse or guarantee a particular hospital, treatment, appointment, clinical decision, or outcome. Current services, requirements, language support, availability, and clinical suitability should be confirmed directly with the hospital.
We use essential cookies to make this site work. With your permission, we also use analytics cookies to improve it. See our Cookie Policy for details.
